Following favorable Phase 2 trial findings for its investigational medication REC-4881 in familial adenomatous polyposis (FAP), a rare hereditary illness for which there are no licensed treatments, Recursion Pharmaceuticals’ (NASDAQ:RXRX) shares increased 7% on Monday.
Strong Clinical Results Reported
According to the business, REC-4881 showed quick clinical action, with a 43% median decrease in total polyp load after 12 weeks of therapy and reductions in 75% of evaluable patients. Remarkably, 82% of patients sustained long-lasting decreases with a median reduction from baseline of 53% even 12 weeks after quitting treatment.
When compared to natural history data, which indicates that 87% of untreated FAP patients usually see an increase in polyp load with time, these results are quite noteworthy. Additionally, 40% of patients showed a clinically significant improvement in their Spigelman stage, a gauge of the severity of upper gastrointestinal disorders.
Sustained Clinical Benefits Noted
Jessica Stout, principal investigator of the TUPELO study and assistant clinical professor at the University of Utah School of Medicine, stated, “The sustained effect seen at Week 25, 12 weeks after completing therapy—especially the durable polyp burden reduction demonstrated by REC-4881—is highly encouraging for the FAP community.”
Recursion’s artificial intelligence platform, the Recursion OS, helped identify REC-4881, an allosteric MEK1/2 inhibitor. With the majority of treatment-related adverse events being Grade 1 or 2 and no Grade 4 or higher occurrences recorded, the business observed that the safety profile was consistent with MEK1/2 inhibition.
Recursion intends to work with the FDA in the first half of 2026 to optimize the dose schedule, increase the number of eligible patients, and outline a possible registration pathway.
Sensex Crashes 610 Points, Nifty Below 26,000
Market Close | Sensex down 610 points, Nifty falls below 26,000, and all sectors are down
On December 8, Indian market indexes concluded poorly, with the Nifty falling below 26,000. At closure, the Nifty was down 225.90 points, or 0.86 percent, at 25,960.55, while the Sensex was down 609.68 points, or 0.71 percent, at 85,102.69.
We will return tomorrow morning with all the most recent information and alerts after concluding today’s Moneycontrol live market blog. For all the worldwide market activity, please visit https://www.moneycontrol.com/markets/global-indices.
Small-Cap Stock Under ₹100 Hits Upper Circuit as Elitecon International Surges 5%
In an otherwise sluggish market, Elitecon International shares were trapped at the 5% upper circuit limit on Monday, December 8, at ₹90.20 each due to a significant increase in trading volume, which was 3.72 lakh on the BSE.
In a report to the markets on Friday, the business stated that, precisely in compliance with the declaration of November 5, 2025, and the Record Date of November 12, 2025, it has paid the whole amount of the interim dividend to all qualified Non-Promoter Category Shareholders.
For the fiscal year 2025–2026, the business announced an interim dividend of 5% per equity share (face value of Rs. 1 each) on November 5. It set November 12, 2025 as the record date for identifying eligible shareholders for the dividend.
Dividend Payout Fully Completed
In its regulatory filing, the business stated, “The interim dividend has been paid to all non-promoter shareholders as per the declaration dated November 5, 2025, and Record Date November 12, 2025.”
Such relinquishment has no effect on the company’s shareholding arrangement. Promoters controlled 59.4% of the firm at the end of the September quarter, followed by FIIs with 38.2% and public shareholders with 2.4%.
According to Trendlyne statistics, the stock has experienced strong selling pressure in recent months, dropping drastically by 78% from the August highs of 422.65 per share.
Concerning Elitecon International
In both local and foreign markets, the firm manufactures and sells cigarettes, smoking mixes, sheesha, and other associated tobacco products. In addition to its other product lines, which include chewing tobacco, snuff grinders, match lights, matches, matchboxes, pipes, and other goods, it presently operates in the United Arab Emirates, Singapore, Hong Kong, and other European nations, including the United Kingdom.
While bolstering its agri-commodities vertical in rice, pulses, and dried fruits, the business is aggressively growing into FMCG categories including packaged foods, edible oils, and drinks.
The board of directors has approved a ₹300 crore financing through a Qualified Institutional Placement (QIP) to support this expansion and expand its worldwide footprint with a pipeline of sustainable, future-ready products.
In order to increase market presence and take advantage of operational synergies, the business claims that the money obtained would be utilized to buy high-potential FMCG companies through its fully owned subsidiary.
Ganesh Sankaran Appointed Head of Wholesale Banking at IndusInd Bank; Stock Drops Over 3%
Ganesh Sankaran has been named Head of Wholesale Banking Group by IndusInd Bank Ltd., effective Monday, December 8, 2025. In a filing with the BSE, the bank stated that he will be a member of the Senior Management Personnel.
Sankaran has over three decades of expertise in wholesale banking, retail credit and SME markets. He has held top executive positions with significant private sector lenders throughout his career, such as Federal Bank, HDFC Bank, and Axis Bank.
Stock Declines Over Three Percent
Building business verticals, spearheading significant business transformations, and overseeing credit, risk, and product activities in addition to board-level duties are all part of his professional expertise.
He has held positions on the boards of Fedbank Financial Services, Equirus Capital, and Axis Capital. In addition, he was a board member and executive director of Federal Bank.
In a different development, the private lender clarified a news article titled “Hindujas looking for strategic partner in IndusInd Bank, but will not dilute stake” by saying that the bank is still well-capitalized and in line with its strategic roadmap and that no talks are in progress to onboard any strategic partner.
In the meantime, IndusInd Bank’s shares ended Monday at Rs 841.25, down 3.30%.
